Citadel Advisors
NAMS icon

Citadel Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Citadel Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
645,805
-66,259
-9% -$2.18M ﹤0.01% 2448
2026
Q1 		$22.8M Buy
712,064
+76,817
+12% +$2.5M ﹤0.01% 2172
2025
Q4 		$22.3M Buy
635,247
+428,786
+208% +$15.6M ﹤0.01% 2227
2025
Q3 		$5.87M Sell
206,461
-113,682
-36% -$2.73M ﹤0.01% 4061
2025
Q2 		$5.8M Sell
320,143
-361,790
-53% -$6.6M ﹤0.01% 3859
2025
Q1 		$14M Sell
681,933
-293,898
-30% -$6.53M ﹤0.01% 2446
2024
Q4 		$25.1M Buy
975,831
+453,366
+87% +$9.63M ﹤0.01% 1921
2024
Q3 		$8.67M Buy
522,465
+308,311
+144% +$5.33M ﹤0.01% 3140
2024
Q2 		$4.11M Sell
214,154
-240,180
-53% -$4.82M ﹤0.01% 4059
2024
Q1 		$10.7M Buy
454,334
+433,288
+2,059% +$8.79M ﹤0.01% 2857
2023
Q4 		$235K Sell
21,046
-10,351
-33% -$94.8K ﹤0.01% 9632
2023
Q3 		$290K Buy
+31,397
New +$340K ﹤0.01% 9242

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Citadel Advisors's NAMS Position: Q2 2026 in Review

Citadel Advisors reduced its NewAmsterdam Pharma (NAMS) stake by 9.3% in Q2 2026, selling an estimated $2.18M and leaving 645,805 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Citadel Advisors first reported a position in NAMS in Q3 2023 and has held it in 12 quarters since. The position peaked at $25.1M in Q4 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Citadel Advisors held 645,805 shares of NewAmsterdam Pharma worth $21.9M as of Q2 2026.
  • Citadel Advisors sold 66,259 NewAmsterdam Pharma shares in Q2 2026, an estimated $2.18M.
  • NewAmsterdam Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2448 holding.
  • Citadel Advisors first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 12 quarters since.
  • Citadel Advisors's NewAmsterdam Pharma position peaked at $25.1M in Q4 2024.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.